Vertex Pharmaceuticals (XTER:VX1) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:VX1 Vertex Pharmaceuticals Inc XTER:VX1
86 GF Score
Price €417.80
GF Value €443.14
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Vertex Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

XTER:VX1 vs REGN, ALNY, RVMD: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Vertex Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vertex Pharmaceuticals Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.


XTER:VX1
86GF Score
Vertex Pharmaceuticals Inc XTER:VX1
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vertex Pharmaceuticals (XTER:VX1) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €417.80 is trading 5.7% below its estimated GF Value™ of €443.14. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for XTER:VX1:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €443.14 vs. price of €417.80 (5.7% below fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the XTER:VX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
86GF Score

Get the complete analysis for XTER:VX1

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€417.80
Price
€443.14
GF Value